Why the study?
Runx1 induction is associated with adverse cardiac remodeling, but the specific cell types responsible for these effects were not established.
Does conditional ablation of Runx1 in fibroblasts or cardiomyocytes protect against adverse cardiac remodeling and dysfunction following myocardial infarction in mice?
Does conditional ablation of Runx1 in fibroblasts or cardiomyocytes protect against adverse cardiac remodeling and dysfunction following myocardial infarction in mice?
Ablation of Runx1 in activated fibroblasts, but not in cardiomyocytes, protects against adverse cardiac remodeling and preserves cardiac function after myocardial infarction, highlighting fibroblasts as a primary therapeutic target for Runx1 inhibition.
May identify fibroblast Runx1 as a remodeling target post-MI; hypothesis-generating and requires human validation.
Runx1 is strongly induced in the heart after acute injury and in chronic disease settings. Its expression negatively correlates with outcomes, and past work demonstrates a protective effect when Runx1 is inhibited through a variety of experimental means. We sought to establish which Runx1-expressing cell type(s) are responsible for the adverse remodeling phenotypes observed upon its induction. Using distinct Cre drivers, we ablated Runx1 from cardiomyocytes and fibroblasts. Following experimental myocardial infarction, we established that loss of Runx1 in fibroblasts, but not cardiomyocytes, is able to protect from adverse remodeling.
No takes yet. Share an insight, caveat, or question.
Akins et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: